Quantcast

Latest Sevelamer Stories

2014-08-06 12:29:28

Nephrologists Seem More Confident That an Iron-Based Phosphate Binder Will Impact the Use of IV Iron vs. the Use of ESAs, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that there is a high need for new phosphate binders to treat hyperphosphatemia among surveyed U.S. nephrologists (n=102). Phosphate binders with fewer pills, better efficacy in reducing serum phosphorous and improved tolerability are rated as...

2014-05-15 08:32:20

Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that it has received a $25 million milestone payment from AstraZeneca (NYSE:AZN, LON:AZN) for the initiation of a Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia, or elevated...

2014-04-22 12:30:10

Improved Pill Burden Scored Highest in Terms of Delivery Attributes, According to Findings from Decision Resources Group BURLINGTON, Mass., April 22, 2014 /PRNewswire/ -- Decision Resources Group finds that reduction in mortality, reduction in serum phosphorus levels, followed by improvement in renal anemia parameters were selected by surveyed nephrologists as the top three most persuasive efficacy clinical trial end points when prescribing a new drug for the treatment of hyperphosphatemia....

2013-04-19 14:26:14

Dietary restriction may be the best way to reduce phosphate's negative effects on the heart Highlights: -The phosphate binder sevelamer carbonate did not improve cardiovascular measures in patients with early chronic kidney disease. -For now, reducing dietary intake of phosphate may be the best way for these patients to reduce the mineral's negative effects on the heart. -High phosphate levels–in kidney disease patients and in the general population–increase the risk of...

2012-07-20 12:16:47

Longest placebo-controlled trial of phosphate binders conducted to date challenges the drugs' utility Highlights: -Phosphate binders, drugs commonly prescribed to patients with chronic kidney disease, may not be as effective as previously thought. -Phosphate binders may have negative effects on cardiovascular health. -Additional studies are needed on the safety and effectiveness of these drugs. Drugs commonly prescribed to patients with chronic kidney disease (CKD) may not be as...

2010-07-15 07:00:00

EXTON, Pa., July 15 /PRNewswire/ -- BioTrends Research Group, Inc. has released two new syndicated market research reports evaluating the nephrology market in Europe. The reports, TreatmentTrends®: Renal Anemia and TreatmentTrends®: Bone and Mineral Metabolism, are derived from the responses of over 200 European nephrologists polled in May and June, 2010 regarding their approach to managing renal anemia and bone and mineral disturbances in their dialysis...

2010-05-25 15:40:00

MORRISTOWN, N.J., May 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market sevelamer carbonate 800mg tablets. Watson's sevelamer carbonate tablet is the generic version of Genzyme's Renvela®. Renvela ® is a phosphate binder indicated for the control...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related